APA (7th ed.) Citation

Nikiforow, S., Werner, L., Murad, J., Jacobs, M., Johnston, L., Patches, S., . . . Baumeister, S. H. (2016). Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. Blood, 128(22), 4052. https://doi.org/10.1182/blood.V128.22.4052.4052

Chicago Style (17th ed.) Citation

Nikiforow, Sarah, et al. "Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma." Blood 128, no. 22 (2016): 4052. https://doi.org/10.1182/blood.V128.22.4052.4052.

MLA (9th ed.) Citation

Nikiforow, Sarah, et al. "Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma." Blood, vol. 128, no. 22, 2016, p. 4052, https://doi.org/10.1182/blood.V128.22.4052.4052.